In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling

Antibody-Fc receptor (FcR) interactions play an important role in the mechanism of action of most therapeutic antibodies against cancer. Effector cell activation through FcR triggering may induce tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). Reciprocally, FcR cross-linking...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2010-04, Vol.70 (8), p.3209-3217
Main Authors: de Haij, Simone, Jansen, J H Marco, Boross, Peter, Beurskens, Frank J, Bakema, Jantine E, Bos, Desiree L, Martens, Anton, Verbeek, J Sjef, Parren, Paul W H I, van de Winkel, Jan G J, Leusen, Jeanette H W
Format: Article
Language:English
Subjects:
Amino Acid Motifs
Amino Acid Sequence
Animals
Antibodies - chemistry
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 - chemistry
Apoptosis
Humans
Immunotherapy - methods
Melanoma, Experimental
Mice
Mice, Transgenic
Molecular Sequence Data
Mutation
Receptor, Epidermal Growth Factor - metabolism
Receptors, Fc - chemistry
Rituximab
Sequence Homology, Amino Acid
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody-Fc receptor (FcR) interactions play an important role in the mechanism of action of most therapeutic antibodies against cancer. Effector cell activation through FcR triggering may induce tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). Reciprocally, FcR cross-linking of antibody may lead to the induction of apoptotic signaling in tumor cells. The relative importance of these bisecting pathways to in vivo antibody activity is unknown. To unravel these roles, we developed a novel mouse model with normal FcR expression but in which FcR signaling was inactivated by mutation of the associated gamma-chain. Transgenic mice showed similar immune complex binding compared with wild-type mice. In contrast, ADCC of cells expressing frequently used cancer targets, such as CD20, epidermal growth factor receptor, Her2, and gp75, was abrogated. Using the therapeutic CD20 antibodies ofatumumab and rituximab, we show that FcR cross-linking of antibody-antigen immune complexes in the absence of gamma-chain signaling is insufficient for their therapeutic activity in vivo. ADCC therefore represents an essential mechanism of action for immunotherapy of lymphoid tumors.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.can-09-4109